Early Diagnosis and Screening for Ovarian Cancer

Mark H. Einstein, Carolyn D. Runowicz

Research output: Chapter in Book/Report/Conference proceedingChapter

1 Citation (Scopus)

Abstract

This chapter reviews some of the cellular and pathologic models that support a multistep oncogenic process from a single ovarian epithelial cell that that provides a rationale for screening. The chapter discusses risk factors and current screening guidelines. Making a diagnosis of early stage ovarian cancer is an extremely difficult task. However, survival is better in early-stage ovarian cancer leading to attempts being made for early detection through tumor markers and screening strategies. CA125 is one of the widely used tumor markers, that has proved beneficial in the detection of ovarian cancer. Other methods used for cancer screening include: ultrasonography and morphology scoring indices. Early symptoms of ovarian cancer are varied and include: abdominal discomfort, dyspepsia, flatulence, bloating, mild digestive disturbances, and pelvic pain. The time required to develop an invasive cancer is unknown. Early detection is significant for improved treatment outcome, as measured by a reduction in morbidity and mortality, in a group of individuals at risk for developing this disease. It is important for all the women to undergo annual pelvic examination as part of routine medical care. The long-term goal of screening approaches is to prevent the onset of the disease by risk-reduction interventions, including chemoprevention and prophylactic surgery.

Original languageEnglish (US)
Title of host publicationDiagnosis and Management of Ovarian Disorders: Second Edition
PublisherElsevier Inc.
Pages219-229
Number of pages11
ISBN (Print)9780120536429
DOIs
StatePublished - Sep 2003

Fingerprint

Ovarian Neoplasms
Early Diagnosis
Screening
Tumor Biomarkers
Flatulence
Gynecological Examination
Pelvic Pain
Dyspepsia
Chemoprevention
Ultrasonography
Risk Reduction Behavior
Early Detection of Cancer
Health care
Epithelial Cells
Surgery
Guidelines
Morbidity
Survival
Mortality
Neoplasms

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)

Cite this

Einstein, M. H., & Runowicz, C. D. (2003). Early Diagnosis and Screening for Ovarian Cancer. In Diagnosis and Management of Ovarian Disorders: Second Edition (pp. 219-229). Elsevier Inc.. https://doi.org/10.1016/B978-012053642-9/50023-5

Early Diagnosis and Screening for Ovarian Cancer. / Einstein, Mark H.; Runowicz, Carolyn D.

Diagnosis and Management of Ovarian Disorders: Second Edition. Elsevier Inc., 2003. p. 219-229.

Research output: Chapter in Book/Report/Conference proceedingChapter

Einstein, MH & Runowicz, CD 2003, Early Diagnosis and Screening for Ovarian Cancer. in Diagnosis and Management of Ovarian Disorders: Second Edition. Elsevier Inc., pp. 219-229. https://doi.org/10.1016/B978-012053642-9/50023-5
Einstein MH, Runowicz CD. Early Diagnosis and Screening for Ovarian Cancer. In Diagnosis and Management of Ovarian Disorders: Second Edition. Elsevier Inc. 2003. p. 219-229 https://doi.org/10.1016/B978-012053642-9/50023-5
Einstein, Mark H. ; Runowicz, Carolyn D. / Early Diagnosis and Screening for Ovarian Cancer. Diagnosis and Management of Ovarian Disorders: Second Edition. Elsevier Inc., 2003. pp. 219-229
@inbook{8fbbc594471745699425b1cbaca0e864,
title = "Early Diagnosis and Screening for Ovarian Cancer",
abstract = "This chapter reviews some of the cellular and pathologic models that support a multistep oncogenic process from a single ovarian epithelial cell that that provides a rationale for screening. The chapter discusses risk factors and current screening guidelines. Making a diagnosis of early stage ovarian cancer is an extremely difficult task. However, survival is better in early-stage ovarian cancer leading to attempts being made for early detection through tumor markers and screening strategies. CA125 is one of the widely used tumor markers, that has proved beneficial in the detection of ovarian cancer. Other methods used for cancer screening include: ultrasonography and morphology scoring indices. Early symptoms of ovarian cancer are varied and include: abdominal discomfort, dyspepsia, flatulence, bloating, mild digestive disturbances, and pelvic pain. The time required to develop an invasive cancer is unknown. Early detection is significant for improved treatment outcome, as measured by a reduction in morbidity and mortality, in a group of individuals at risk for developing this disease. It is important for all the women to undergo annual pelvic examination as part of routine medical care. The long-term goal of screening approaches is to prevent the onset of the disease by risk-reduction interventions, including chemoprevention and prophylactic surgery.",
author = "Einstein, {Mark H.} and Runowicz, {Carolyn D.}",
year = "2003",
month = "9",
doi = "10.1016/B978-012053642-9/50023-5",
language = "English (US)",
isbn = "9780120536429",
pages = "219--229",
booktitle = "Diagnosis and Management of Ovarian Disorders: Second Edition",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Early Diagnosis and Screening for Ovarian Cancer

AU - Einstein, Mark H.

AU - Runowicz, Carolyn D.

PY - 2003/9

Y1 - 2003/9

N2 - This chapter reviews some of the cellular and pathologic models that support a multistep oncogenic process from a single ovarian epithelial cell that that provides a rationale for screening. The chapter discusses risk factors and current screening guidelines. Making a diagnosis of early stage ovarian cancer is an extremely difficult task. However, survival is better in early-stage ovarian cancer leading to attempts being made for early detection through tumor markers and screening strategies. CA125 is one of the widely used tumor markers, that has proved beneficial in the detection of ovarian cancer. Other methods used for cancer screening include: ultrasonography and morphology scoring indices. Early symptoms of ovarian cancer are varied and include: abdominal discomfort, dyspepsia, flatulence, bloating, mild digestive disturbances, and pelvic pain. The time required to develop an invasive cancer is unknown. Early detection is significant for improved treatment outcome, as measured by a reduction in morbidity and mortality, in a group of individuals at risk for developing this disease. It is important for all the women to undergo annual pelvic examination as part of routine medical care. The long-term goal of screening approaches is to prevent the onset of the disease by risk-reduction interventions, including chemoprevention and prophylactic surgery.

AB - This chapter reviews some of the cellular and pathologic models that support a multistep oncogenic process from a single ovarian epithelial cell that that provides a rationale for screening. The chapter discusses risk factors and current screening guidelines. Making a diagnosis of early stage ovarian cancer is an extremely difficult task. However, survival is better in early-stage ovarian cancer leading to attempts being made for early detection through tumor markers and screening strategies. CA125 is one of the widely used tumor markers, that has proved beneficial in the detection of ovarian cancer. Other methods used for cancer screening include: ultrasonography and morphology scoring indices. Early symptoms of ovarian cancer are varied and include: abdominal discomfort, dyspepsia, flatulence, bloating, mild digestive disturbances, and pelvic pain. The time required to develop an invasive cancer is unknown. Early detection is significant for improved treatment outcome, as measured by a reduction in morbidity and mortality, in a group of individuals at risk for developing this disease. It is important for all the women to undergo annual pelvic examination as part of routine medical care. The long-term goal of screening approaches is to prevent the onset of the disease by risk-reduction interventions, including chemoprevention and prophylactic surgery.

UR - http://www.scopus.com/inward/record.url?scp=0042647168&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0042647168&partnerID=8YFLogxK

U2 - 10.1016/B978-012053642-9/50023-5

DO - 10.1016/B978-012053642-9/50023-5

M3 - Chapter

SN - 9780120536429

SP - 219

EP - 229

BT - Diagnosis and Management of Ovarian Disorders: Second Edition

PB - Elsevier Inc.

ER -